Anergis to Present Dose-Dependent Immunological Effects of Ultra-Fast Allergy Immunotherapy AllerT at the AAAAI annual meeting

- Marked increases in Bet v 1 specific IgG4 were dose-dependent in 213 patients allergic to birch pollen

EPALINGES, Switzerland, March 1, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it will present new dose-ranging data on its lead-product AllerT at the AAAAI annual meeting. The annual meeting of the AAAAI (American Academy of Allergy, Asthma and Immunology) will take place in Atlanta, USA, from March 3 to 6, 2017.

The following scientific communication will be presented during the meeting:

Presentation Title: "Dose dependent increase of Bet v 1 specific IgG4 after Bet v 1 COP therapy"
Presenter: Alexander Kettner, Ph.D
Time and Date: Monday, March 6, 2017, 9.45 am-10.45 am
Session: 4210 ; Allergen Extracts and Other Forms of Immunotherapy
Poster #: 804
Location: Georgia World Congress Center, Level One, South Exhibit Hall B2

***

About Anergis

Anergis SA is a Swiss biopharmaceutical company dedicated to the discovery and development of novel, ultra-fast, proprietary allergy immunotherapy products for the most prevalent allergies. Anergis’ lead-product against birch pollen allergies, AllerT, is in Phase II clinical development. Two additional product candidates against ragweed pollen (AllerR) and house dust mite allergies (AllerDM) are in preclinical development.

Anergis has raised approximately CHF 52 million from private and institutional investors, including BioMedInvest, Renaissance PME, Sunstone Capital, and WJFS, Inc.

About Allergies

Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world, affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization”, “allergy shots” or “Conventional
Allergy Immunotherapy” (AIT), is the process of inducing tolerance to the allergen. It typically requires 3-5 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (<30 min) anaphylactic reactions – which can be life-threatening. With its technology, Anergis is shaping the future of allergy treatment by developing therapeutic modalities that only require 2 months of treatment - compared to 3 to 5 years with currently marketed products.

About Ultra-fast Allergy Immunotherapy and AllerT

AllerT is Anergis’ ultra-fast allergy immunotherapy (AIT) against birch pollen allergy originating from the company’s proprietary Contiguous Overlapping Peptide (COP) technology platform. COPs are long synthetic peptides that include the full amino acid sequence of one or more natural allergens, which are devoid of the IgE epitopes responsible for the risk of anaphylaxis during immunotherapy with allergens. COP allergy immunotherapy is “ultra-fast” because it only requires a single, 2-month course of treatment to induce long-lasting allergy symptom relief – without repeated treatment in following years.

Today, AllerT is the only ultra-fast AIT treatment with demonstrated clinical efficacy in real-life field-based trials for two consecutive annual pollen seasons and persistent statistically significant elevation in specific immunoglobulin G4 (IgG4) for four consecutive annual pollen seasons, without repeated treatment after the initial 2-month course.